Prox1-CreERT2 Mouse

Random Transgenic

Prox1-CreERT2 Random Transgenic Mouse Model
This line is cryopreserved and requires cryorecovery.

C57BL6 Background

  • Model #
  • Genotype
  • Nomenclature
  • 14092-F
  • 14092-M
  • An inducible cre deleter under the control of the prospero homeobox 1 (Prox1) promoter.
  • Cre recombination is inducible via administration of tamoxifen.
  • Allows specific and temporally controlled cre-loxP recombination (gene inactivation/activation) in Prox1-expressing tissues, including lymphatic endothelia.
  • Efficient recombination is observed during all developmental stages (embryonic, postnatal) and in adults.

    Genetic Background:



    The Prxo1-creERT2 mouse was developed in the laboratory of Taija Makinen at the London Research Institute. A cDNA encoding tamoxifen inducible Cre recombinase (CreERT2) followed by SV40 polyadenylation signal was introduced into the start codon of Prox1 in BAC clone RP23-190F21 using homologous recombination in bacteria. Founder lines were backcrossed to C57BL/6. Taconic received embryos from CRT in 2015.



    Initial Publication:

    Bazigou et al. 2011. Genes regulating lymphangiogenesis control venous valve formation and maintenance in mice. J Clin Invest. Aug 1; 121(8): 2984–2992.

  • Access to this model requires execution of a Limited Breeding Agreement and cryorecovery services to recover the line. Current Limited Breeding Agreement fees for this model are $3,000/€2550 per year for non-profit users and $10,000/€8500 per year for for-profit users. Cryorecovery fees are additional.

    Purchase of line #14092 includes the right under the patents owned by Le Centre Européen de Recherche en Biologie et en Médecine ("CERBM") to perform inducible deletion (e.g. tamoxifen induction based deletion) using the CreER gene.

    Welcome! Tell us a little about yourself